Type One
Investor participating in BioOrbit's £9.8m seed round.
Last refreshed: 1 May 2026 · Appears in 1 active topic
What kind of science-led companies does Type One Ventures back?
Timeline for Type One
Mentioned in: BioOrbit raises £9.8m for orbital pharma
UK Startups and Innovation- What does Type One Ventures invest in?
- Type One Ventures is a seed-stage European VC focused on science-led and deep-tech founders, typically at pre-seed or seed before product-market fit. Its portfolio covers biotech, space, materials and hard-tech sectors where founders bring strong research credentials. It participates in syndicates alongside larger institutional leads rather than leading rounds itself.Source: event
- Why did Type One invest in BioOrbit?
- Type One participated in BioOrbit's £9.8m seed in April 2026 alongside LocalGlobe and Breega. BioOrbit's in-space pharmaceutical manufacturing technology is a science-led deep-tech venture consistent with Type One's thesis.
- What stage does Type One Ventures back companies at?
- Type One Ventures invests at pre-seed and seed, before most companies have established product-market fit. Its small initial cheques allow it to build a broad portfolio and follow conviction bets into later rounds alongside co-investors.Source: event
- Did Type One Ventures invest in BioOrbit?
- Yes. Type One participated in BioOrbit's £9.8m seed round in April 2026, the world's largest seed for in-space drug manufacturing. The syndicate was co-led by LocalGlobe and Breega, with Auxxo, Seedcamp and 7percent also participating.Source: event
- Is Type One Ventures a UK fund?
- Type One Ventures operates as a European early-stage fund with a UK presence. It focuses on science-to-commercial translation across European deep-tech ecosystems and regularly co-invests with UK-based lead funds such as LocalGlobe.
Background
Type One Ventures is a seed-stage venture capital fund investing in science-led and deep-tech founders in Europe. The fund focuses on companies with defensible intellectual property and long-term structural advantage, typically at pre-seed or seed before product-market fit is established. It operates as a participant investor, co-investing in syndicates with larger European and UK-based lead funds.
Type One's portfolio reflects an interest in science-to-commercial translation: biotech, space, materials and hard-tech sectors where the founding team brings research credentials rather than pure product experience. The fund's small cheque sizes allow it to maintain a broad portfolio and follow conviction bets into later rounds alongside co-investors.
Type One participated in BioOrbit's £9.8m in-space drug manufacturing seed in April 2026, alongside LocalGlobe, Breega, Auxxo, Seedcamp and 7percent. The round is the world's largest seed for in-space manufacturing and demonstrates the syndicate model common in European deep-tech, where specialist early-stage funds cluster around regulatory-enabled science companies.